摘要
Abstract
Objective:To observe the clinical present situation of recombinant human coagulation factorⅦa in patients with intractable blood loss, increase awareness about the hemoslatic medicine,improve the clinical application.Method:A retrospective analysis was made to investigate the effect about rFⅦa in patients with intractable blood loss in 40 cases.There were 40 cases,15 cases after cardiac surgery,10 cases after chest surgery,5 cases of hepatobiliary,7 cases of coagulation disorders injury,3 cases of gastrointestinal stress ulcer bleeding.40 cases were treated with rFⅦa.The amount of bleeding, the blood transfusion volume,the total volume of blood transfusion 3 hours before treated with rFⅦa contrast 3 hours after treated with rFⅦa.Result:38 cases were cured successfully,2 cases dead.Conclusion:38 cases treated with rFⅦa,after 3 hours the amount of bleeding were sharp reducing,the blood transfusion volume and the total volume of blood transfusion were sharp slowdown.Patients with intractable blood loss,the conventional method unable valid stanch bleeding, ought to positive recommend treaded with rFⅦa.关键词
重组人凝血因子Ⅶa/难治性出血/临床观察Key words
rFⅦa/Intractable blood loss/Clinical observation分类
医药卫生
